Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H31N3O2S |
Molecular Weight | 425.587 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN4CCN(CCO)CC4)C2=C1
InChI
InChIKey=XZSMZRXAEFNJCU-UHFFFAOYSA-N
InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DescriptionSources: http://www.tabletwise.com/us/proketazine-tabletCurator's Comment: description was created based on several sources, including:
http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601
Sources: http://www.tabletwise.com/us/proketazine-tablet
Curator's Comment: description was created based on several sources, including:
http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601
Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura.
CNS Activity
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years Health Status: unhealthy Age Group: 18 - 60 years Sex: F Sources: |
Disc. AE: Skin rash... Other AEs: Faintness... AEs leading to discontinuation/dose reduction: Skin rash (grade 4, 1 patient) Other AEs:Faintness (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Faintness | 1 patient | 100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years Health Status: unhealthy Age Group: 18 - 60 years Sex: F Sources: |
Skin rash | grade 4, 1 patient Disc. AE |
100 mg 4 times / day steady, oral Dose: 100 mg, 4 times / day Route: oral Route: steady Dose: 100 mg, 4 times / day Sources: |
unhealthy, 18 - 60 years Health Status: unhealthy Age Group: 18 - 60 years Sex: F Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14218188
First week, 25 mg. t.i.d.; second week, 50 mg. t.i.d.; third week, 75 mg. t.i.d.; fourth week, 100 mg. t.i.d.; fifth week and thereafter, 100 mg. q.i.d.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2622-30-2
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
516
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
DB01038
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
C73285
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
m1057
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | Merck Index | ||
|
220-072-9
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
CLY16Y8Z7E
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
51235
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
Carfenazine
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201328
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
7140
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
DTXSID8022745
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
1179
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
18104
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
100000084572
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY | |||
|
SUB06625MIG
Created by
admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)